Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Targeting therapy in Epidermal growth factor

The Epidermal Growth Factor Receptor (EGFR), or ErbB1, is a member of the ErbB family of tyrosine kinase receptors. It is a 170 kDa transmembrane glycoprotein that can bind a variety of ligands on its extracellular domain, most notably Epidermal Growth Factor (EGF). Binding of ligand induces homo- or heterodimerization with a second EGFR molecule or another member of the ErbB family, respectively. Once dimerized, the molecule undergoes auto-phosphorylation on intracellular tyrosine residues. Phosphorylation of these tyrosine residues allows for recruitment of ATP to the catalytic kinase domain of EGFR, which allows for phosphorylation of effector molecules.

Related articles in Tumour Therapy http://www.scitechnol.com/scholarly/tumor-therapy-journals-articles-ppts-list.php

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top